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Dear Editor,
Gastric cancer is mostly diagnosed at advanced stag-
es and in that case palliative treatment is the choice. 
In advanced stages better outcomes has been shown 
with chemotheurapeutics such as docetaxel, 5-FU, 
cisplatin, epirubicin and in Japan S1. Mostly combi-
nation regimens are studied; docetaxel, cisplatin and 
5-FU combination has shown better outcomes and 
higher response rates.1
Pericardial effusion is a rare complication in cancer 
patients. Malignant infiltration of heart and pericar-
dium can be seen in lymphoma, melanoma, lung and 
breast cancers. The mechanism of pericardial effu-
sion can be either increase in intrapericardial pressure 
through the obstruction of lymphatics and venous 
drainage of the heart or direct invasion of pericar-
dium. Dyspnea, fatigue, cough and chest pain are the 
main symptoms. Neck vein distension and pericar-
dial frotman can be detected on physical examination 
and increase in cardiothoracic ratio on plain film. The 
exact diagnosis is via echocardiography.2
To our knowledge, in the literature there are only a 
few cases of pericardial effusion occurring  during 
the course or after the treatment of gastric cancer. 
Instead in most of the cases the effusion is accompa-
nied by malignant infiltration. 
In this paper, two cases are reported in whom peri-
cardial effusion occurred after treatment to stress on 
probability treatment complication. 
Case 1: 32 years old female admitted to hospital 
with total body pain and dyspepsia. In blood analy-
ses, ALP level was quite high. By further examina-
tion multipl lytic lesions were detected on her bones. 
In upper gastrointestinal system endoscopy a prob-
able malign ulcer is detected and the biopsy revealed 
adenocarcinoma. Her echocardiography and cardiac 
examination was quite normal. 
With a diagnosis of metastatic gastric carcinoma, the 
treatment was planned as zoledronic acid plus DCF 
(docetaxel, cisplatin and 5-Fluorouracil) On the 5th 
day of chemo, because of dyspnea and tachycardia, 
Echo was planned and a newly occuring pericardial 
effusion was detected. Chemo was stopped and be-
cause of the risk of tamponade she was transfered to 
coronary intensive care unit. Colchicine was added 
to her treatment and in the follow up her clinic im-
proved. After her symptoms completely resolved, 
she was discharged from hospital with colchicine. 
When she admitted for the second cycle of chemo, 
in repeated echocardiography pericardial effusıon 
was detected and second cycle couldn’t be given. 
During follow-up cardiac tamponade developed and 
therapeutic pericardiosynthesis and drainage was 
performed. Cytologic examination of effusion was 
reported as benign and no microorganisms detected 
in the culture. Unfortunately she perished because of 
cardiac tamponade. 
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Case 2: 61 years old male was diagnosed as gas-
tric malignancy and total gastrectomy+lymph node 
dissection was performed. Pathologic examination 
revealed a  pT3N3Mx mucinous adenocarcinoma 
and he was directed to our clinic for adjuvant treat-
ment. 
Adjuvant chemoradiation was decided and  com-
pleted without any complication During follow-up 
(on 10th month after surgery) a 2,5 cm mass in left 
lung paranchyma and an increase in tumor markers 
were detected. He was accepted as metastatic gastric 
cancer and palliative treatment was planned. Pretreat-
ment echocardiography was normal, but since cre-
atinin clerance level was< 50 ml/min, docatexel, car-
boplatin and 5-FU combination was started. After the 
completion of first cycle, a rise in SGOT,and SGPT 
levels was detected.  Further examination revealed 
pericardial effusion and after cardiology department 
evaluation colchicine was added to the treatment. 
After the effusion mostly resolved the chemotherapy 
was changed to epirubicine, 5-FU and carboplatin. 
With this combination he completed the cycles with-
out any other complications. 
Pericardial effusion during the course of gastric can-
cer is a rare entity and in the literature only a few 
case reports mostly from Japan have been presented. 
These cases have all been suggested as metastases. 
Some of the chemotheurapeutics are known to have 
cardiac side effects. 5-FU and Capecitabine are re-
sponsible from ischemic angina or congestive heart 
failure. Cisplatin may cause arythmia and congestive 
heart failure.3
For docatexel peripheral edema, pleural effusion, 
ascites and rarely pericardial effusion have been re-
ported in the literature. Our cases used to have nor-
mal pretreatment cardiographic evaluation and after 
the treatment pericardial effusion was detected. In 
a phase II study in which docetaxel was used in the 
treatment of non-small cell lung cancer, Fosella et al 
have reported pericardial effusion in one cases during 
docetaxel treatment.4,5
Vincenzi et al reported two cases of patients who de-
veloped repeated episodes of pericardial effusion af-
ter docetaxel infusion. In one of the cases pericardial 
effusion preceded to pericardial tamponade. Pericar-
diosynthesis was done and revealed benign cytology. 
Since the patient had responded well to docetaxel 
treatment, it was continued. But in the following 
cycles pericardial effusion and tamponade was re-
peated, pericardiotomy was to be done and the treat-
ment was replaced by vinorelbine. In another case of 
malignant epithelial tumor of unknown origin, after 5 
cycles of gemcitabine+docetaxel combination, peri-
cardial effusion has been detected. The cytology was 
benign. Once pericardial effusion occurred, chemo-
therapy was changed and effusion did not occur 
again.6 Just as the cases Vincenzi et al reported, in our 
cases pericardial effusion occurred after docetaxel 
treatment also.  In one of our cases when docetaxel 
was changed in the combination, the effusion didn’t 
reoccur. In the second case, unfortunatelly there was 
no time to change the chemo since the period was 
quite deleterious.  In our cases the time of pericardial 
effusion was just after the first cycle, different from 
the other cases in literature.  
It must be kept in mind that, when chemotheurapeu-
tics having cardiac side effects are to be used, con-
stitutional symptoms such as dyspnea and chest pain 
can be alerting signs of pericardial effusion and even 
tamponade. 
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